# Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases

> **NCT05903937** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Vastra Gotaland Region** · enrollment: 6 (estimated)

## Conditions studied

- Uveal Melanoma
- Metastatic Cutaneous Melanoma

## Interventions

- **DRUG:** Autologous Tumor Infiltrating Lymphocytes
- **DRUG:** Melphalan
- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT05903937
- **Lead sponsor:** Vastra Gotaland Region
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-12-31
- **Primary completion:** 2024-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05903937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05903937, "Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05903937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*